Francine Foss, MD
Medical Oncology · New Haven, CTNPI 1104814888
Payments from drug & device makers
Across 538 payments — averaging $3796.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kyowa Kirin, Inc.$894K
- Otsuka Pharmaceutical Co., Ltd.$319K
- Eisai Inc.$317K
- Daiichi Sankyo Inc.$217K
- Seagen Inc.$130K
- Acrotech Biopharma Inc.$43K
- plus $122K from 14 others
Across 9 payments — averaging $1147.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$10K
What the payments were for
- Consulting fees$68,67836%
- Speaking & faculty fees$101,02452%
- Travel & lodging$18,3219%
- Food & beverage$4,8533%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kyowa Kirin, Inc. | 39 | $893,859 |
| Otsuka Pharmaceutical Co., Ltd. | 64 | $319,095 |
| Eisai Inc. | 201 | $317,497 |
| Daiichi Sankyo Inc. | 76 | $216,823 |
| Seagen Inc. | 76 | $130,179 |
| Acrotech Biopharma Inc. | 27 | $42,926 |
| Mallinckrodt Enterprises LLC | 11 | $33,499 |
| Taiho Oncology, Inc. | 10 | $26,446 |
| Merck | 2 | $24,300 |
| Kyowa Kirin Pharmaceutical Development, Inc | 2 | $12,192 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $6,426 |
| Aurobindo Pharma USA, Inc. | 4 | $5,950 |
| Helsinn Healthcare SA | 1 | $4,500 |
| Verastem, Inc. | 2 | $2,739 |
| Pfizer | 6 | $2,309 |
| Secura Bio, Inc. | 8 | $1,924 |
| Kyowa Kirin Services Ltd | 1 | $1,692 |
| AstraZeneca | 2 | $225 |
| TG Therapeutics, Inc. | 1 | $120 |
| Therakos LLC | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,042,725 in reported general payments places this provider in the 75th percentile of 79 medical oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 13 | $225,427 |
| ZolinzaVorinostat | 12 | $84,195 |
| Bexarotene | 28 | $83,432 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $4,552 |
| Acyclovir | 65 | $869 |
| Levothyroxine Sodium | 25 | $371 |
| Ursodiol | 14 | $368 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 36 | $347 |
| Prednisone | 41 | $303 |
| Cefazolin Sodium | 11 | $300 |
| Potassium Chloride | 27 | $184 |
| Triamcinolone Acetonide | 23 | $183 |
| Hydroxyzine Hcl | 13 | $113 |
| Pantoprazole Sodium | 16 | $105 |
| Rosuvastatin Calcium | 13 | $84 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in New Haven
- Lajos PusztaiNew Haven$23.5M
- Sarah GoldbergNew Haven$17.7M
- Harriet KlugerNew Haven$17.7M
- Daniel PetrylakNew Haven$10M
- Ian KropNew Haven$7.5M
- Anne ChiangNew Haven$5.8M
- Noffar BarNew Haven$5.4M
- Scott GettingerNew Haven$5.1M
- Jill LacyNew Haven$3.5M
- Aarti BhatiaNew Haven$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.